The FDA has approved a generic version of liraglutide (Victoza) for type 2 diabetes in patients aged 10 and older, aiming to expand access amid GLP-1 medication shortages. Developed by Hikma Pharmaceuticals, this daily injectable offers a more affordable alternative, complementing diet and exercise for blood sugar control. The move is part of the FDA’s Drug Competition Action Plan to boost affordability and access to complex generics.
Keep Reading
Add A Comment